| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | NS; E2IG3; NNP47; C77032 |
| WB Predicted band size | 62 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human GNL3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于GNL3抗体的参考文献及其简要摘要：
---
1. **文献名称**: *"A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells"*
**作者**: Tsai, R. Y., & McKay, R. D.
**摘要**: 该研究首次报道了GNL3(Nucleostemin)在神经干细胞和癌细胞核仁中的特异性表达，并通过免疫荧光和Western blot实验验证其抗体的特异性。研究发现GNL3通过调控核仁功能影响细胞增殖，为干细胞和癌症研究提供了新靶点。
---
2. **文献名称**: *"Nucleostemin expression in invasive breast carcinoma and its relation to pathologic parameters"*
**作者**: Ma, H., et al.
**摘要**: 研究使用GNL3抗体对乳腺癌组织进行免疫组化分析，发现GNL3在恶性肿瘤中高表达，且与肿瘤分级、转移及患者预后不良显著相关，提示其可作为潜在的癌症生物标志物。
---
3. **文献名称**: *"GNL3 controls nucleolar stress-induced senescence through the ribosomal protein-MDM2-p53 pathway"*
**作者**: Beekman, C., et al.
**摘要**: 文章通过GNL3抗体介导的敲低实验，揭示了GNL3在核仁应激反应中的作用机制。实验表明，GNL3通过调控核糖体蛋白-MDM2-p53通路影响细胞衰老，为癌症治疗提供了新思路。
---
4. **文献名称**: *"Nucleostemin regulates glioma stem cell proliferation via interaction with nucleophosmin"*
**作者**: Romanova, M. V., et al.
**摘要**: 研究利用GNL3抗体进行免疫共沉淀和免疫印迹分析，发现GNL3与核磷蛋白(NPM1)相互作用，共同调控胶质瘤干细胞的增殖和自我更新能力，强调了其在肿瘤干细胞维持中的关键作用。
---
以上文献均通过GNL3抗体验证其在细胞定位、蛋白互作或疾病机制中的功能，涉及技术包括免疫组化、Western blot和免疫荧光等。
The guanine nucleotide-binding protein-like 3 (GNL3) antibody is a tool used to study the GNL3 protein, also known as nucleostemin, which plays critical roles in cell proliferation, stem cell maintenance, and cancer progression. GNL3 belongs to the family of GTP-binding proteins localized primarily in the nucleolus, where it regulates ribosomal RNA (rRNA) processing and ribosome biogenesis. It is highly expressed in stem cells, embryonic tissues, and various cancers, including glioblastoma, hepatocellular carcinoma, and breast cancer, where its overexpression correlates with poor prognosis and tumor aggressiveness.
Research using GNL3 antibodies has revealed its involvement in cell cycle regulation, particularly in transitioning cells from quiescence to active proliferation. It interacts with p53 and MDM2. suggesting a role in modulating stress responses and apoptosis. Antibodies against GNL3 enable detection of its expression patterns via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in studies of its subcellular localization and dynamics during differentiation or tumorigenesis.
GNL3 is considered a potential therapeutic target due to its association with cancer stem cells and chemoresistance. However, challenges remain in understanding its precise molecular mechanisms and context-dependent functions. Antibody specificity and validation across experimental models are critical to ensure accurate interpretation in both basic research and clinical applications.
×
